Nov 27, 2023 08:32AM
Nov 27, 2023 08:30AM
Aug 11, 2023 07:00AM
Jul 27, 2023 07:01AM
Jul 27, 2023 07:00AM
Mar 2, 2023 07:01AM
Nov 3, 2022 07:01AM Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates
Oct 4, 2022 07:01AM
Aug 24, 2022 08:01AM
Aug 18, 2022 04:32PM
Aug 18, 2022 04:05PM
Aug 4, 2022 07:01AM
Jun 2, 2022 08:59AM
Jun 2, 2022 08:59AM Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency
May 5, 2022 09:28AM
May 5, 2022 09:28AM
May 5, 2022 06:30AM
Apr 12, 2022 09:23AM
Apr 12, 2022 06:01AM
Apr 12, 2022 06:01AM
Apr 11, 2022 04:31PM Aeglea BioTherapeutics (AGLE) Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase
Apr 11, 2022 04:30PM
Mar 8, 2022 07:02AM
Mar 8, 2022 07:01AM
Dec 6, 2021 06:31AM
Dec 6, 2021 06:30AM
Nov 4, 2021 07:01AM
Nov 4, 2021 06:59AM Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE Study Baseline Characteristics
Aug 5, 2021 08:30AM
Jul 15, 2021 08:30AM
Jul 14, 2021 04:35PM
Jul 14, 2021 04:30PM
May 10, 2021 08:30AM
May 3, 2021 08:33AM
May 3, 2021 08:30AM Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency
Mar 22, 2021 08:30AM
Mar 18, 2021 08:30AM
Dec 17, 2020 04:09PM
Dec 17, 2020 04:05PM
Dec 1, 2020 07:32AM
Dec 1, 2020 07:30AM
Nov 5, 2020 08:30AM Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights
Oct 26, 2020 08:32AM
Oct 26, 2020 08:30AM
May 7, 2020 08:30AM
May 7, 2020 08:30AM
Sep 3, 2019 06:05AM
Sep 3, 2019 06:00AM
Sep 3, 2019 06:00AM Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium
Aug 6, 2019 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All